Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
NCT03706833
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama +102 locations
Conditions: Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Register for Updates
A Randomized Control Trial of Motor-based Intervention for CAS
NCT04642053
Recruiting
Childhood apraxia of speech (CAS) is a complex, multivariate speech motor disorder characterized by difficulty planning and programming movements of the speech articulators (ASHA, 2007; Ayres, 1985; Campbell et al., 2007; Davis et al., 1998; Forrest, 2003; Shriberg et al., 1997). Despite the profound impact that CAS can have on a child's ability to communicate, little data are available to direct treatment in this challenging population. Historically, children with CAS have been treated with art... Read More
Gender:
ALL
Ages:
Between 29 months and 95 months
Trial Updated:
05/19/2025
Locations: New York University, Department of Communicative Sciences & Disordesr, New York, New York
Conditions: Childhood Apraxia of Speech
Register for Updates
B-Complex: A Nutraceutical SANS Countermeasure
NCT05366933
Recruiting
In this project, the investigators propose to test effectiveness of a daily nutraceutical supplement containing bioactive B vitamins to mitigate optic disc edema in astronauts. The proposed countermeasure is intended to maximize functioning of the one-carbon metabolic pathway to provide enough substrate and cofactors to overcome any genetic differences that may impact the efficiency of enzyme function. By optimizing the pathway, this will 1) optimize endothelial function by increasing eNOS coupl... Read More
Gender:
ALL
Ages:
Between 20 years and 100 years
Trial Updated:
05/19/2025
Locations: Johnson Space Center, Houston, Texas
Conditions: Optic Disc Edema, Endothelial Dysfunction
Register for Updates
CARv3-TEAM-E T Cells in Glioblastoma
NCT05660369
Recruiting
The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
Register for Updates
Use of the Neurolyser XR for the Treatment of Low Back Pain Related to Sacroiliitis
NCT06053255
Recruiting
The Neurolyser XR is a device used to deliver high-intensity focused ultrasound for the ablation of the lateral sacral branch nerve in patients with Sacroiliitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: University of Virginia, Department of Anesthesiology, Charlottesville, Virginia
Conditions: Sacroiliitis
Register for Updates
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
NCT06333262
Recruiting
This study will evaluate fixed-duration therapy with pirtobrutinib and obinutuzumab given over 12 cycles (approximately 1 year) as first-line treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL or SLL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: New England Cancer Specialists, Scarborough, Maine +3 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Investigation to Understand and Optimize Psilocybin
NCT06512194
Recruiting
This study will examine the effects of a single dose of psilocybin, administered with psychological support, on symptoms of depression. It will also assess whether different post-dosing interventions, including a non-invasive technique called transcutaneous auricular Vagus Nerve Stimulation (taVNS), influence various psychological and behavioral outcomes. In addition, the study will explore objective measures of real-world social behavior and identify early behavioral responses that may be assoc... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
05/19/2025
Locations: Vail Health Behavioral Health, Edwards, Colorado
Conditions: Depression
Register for Updates
Supplemental Postoperative Bupivacaine Following Non-Surgical Endodontic Treatment
NCT06655454
Recruiting
The study will investigate the impact of an additional injection of long-acting anesthetic on pain level, quality of life, and use of pain medication after a nonsurgical endodontic treatment. The long-acting anesthetic will be compared to a mock injection group and a group with no additional anesthetic to determine any differences in effects.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: New York University College of Dentistry, New York, New York
Conditions: Pain Assessment, Quality of Life (QOL), Analgesic Use
Register for Updates
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
NCT06809595
Recruiting
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
05/19/2025
Locations: Preferred Research Partners, Inc., Little Rock, Arkansas +14 locations
Conditions: Generalized Anxiety Disorder
Register for Updates
A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))
NCT05731128
Recruiting
The protocol of this Phase 2 clinical trial consists of a double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of dupilumab in participants with moderately to severely active Ulcerative Colitis (UC) with an eosinophilic phenotype. Screening period: 2 to up to 4 weeks Treatment period: 52-week investigational medicinal product (IMP) intervention (dupilumab or matching placebo) from Week 0 to Week 52 Open-label arm (optional): administration of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/18/2025
Locations: Om Research- Site Number : 8400029, Apple Valley, California +76 locations
Conditions: Colitis Ulcerative
Register for Updates
Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
NCT06298019
Recruiting
The goal of this clinical trial is to characterize to understand the effects of a type of cell therapy called Chimeric Antigen Receptor T lymphocyte (CAR T) therapy in adult patients with the autoimmune disease dermatomyositis. This study will utilize a technology that modifies a type of white blood cell called the cytotoxic T lymphocyte-this T cell normally functions in the immune system to kill infected or potentially harmful cells in the body. In CAR T therapy, the patients' white blood cells... Read More
Gender:
ALL
Ages:
Between 25 years and 72 years
Trial Updated:
05/18/2025
Locations: Stanford University, Palo Alto, California +1 locations
Conditions: Dermatomyositis
Register for Updates
A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults
NCT06382311
Recruiting
The aim of this study is to evaluate the safety, reactogenicity and immunogenicity of the Flu Pandemic messenger RNA (mRNA) vaccine (including dose-finding and dose-confirmation) administered in healthy adults 18 to 85 years of age.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/18/2025
Locations: GSK Investigational Site, Anniston, Alabama +20 locations
Conditions: Influenza, Human
Register for Updates